glp-1 agonist equivalent doses receptor agonists available Switching between GLP‐1 receptor agonists

after following this regimen for 12 weeks, average weight loss stood at 4.7% of initial body mass (5 kg as an absolute value) and increased to 6% (6.4 kg as an absolute value) when administered doses rose from 1.8 to 3 mg respectively, compared against a mere loss of about 2.2% body mass (which equates to 2.2 kg actual value) among those on placebo

Akimoto H, Negishi A, Oshima S, Wakiyama H, Okita M, Horii N, et al

MASLD, metabolic dysfunction-associated steatotic liver disease

Currently, the single-agonist segment holds the maximum share of the GLP-1 market

The real challenge now is ensuring that increased accessibility does not translate into indiscriminate usage

Type 2 diabetes and GLP-1 RA treatment response It is also important to note that therapeutic responses may differ between patients with and without T2DM, a difference likely driven by several interrelated mechanisms [42]